Clinical Trial Update: The Role of Levosimendan as Inotropic Agent in Acute Aluminum Phosphide-induced Cardiotoxicity [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating levosimendan as an inotropic therapy for aluminum phosphide–induced cardiotoxicity presenting as acute myocarditis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocarditis

Drugs mentioned

• Levosimendan (levosimendan)

Snippet

Sponsor: Ain Shams University | Conditions: Acute Myocarditis | Phase 3 | Status: COMPLETED